Superworth

Iovance Biotherapeutics IOVA

Biotechnology, Healthcare
$8.02
−5.42%
Market cap
$3.6B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
11.2×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$325M
+35% on a year ago
Net margin
−89.1%
Free cash flow yield
−8.2%

Iovance Biotherapeutics trades at 11.2× sales. Revenue was $325M over the last twelve months, up 35% on a year earlier with a −89% net margin.

Charts

Financials

Income statement for IOVA, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$469K$482K$715K$31.1M+12970%$58.6M+12385%$73.7M+15189%$49.3M+6799%$60M+93%$67.5M+15%$86.8M+18%$71.4M+45%$99.3M+66%
Cost of revenue$4.3M$4.4M$7.3M$31.4M+1430%$31.5M+626%$45.5M+943%$42.7M+488%$48.9M+56%$38.5M+22%$43.1M−5%$42.5M−1%$43.6M−11%
Gross profit−$3.9M−$3.9M−$6.5M−$262K−86%$27M$28.2M$6.6M$11.1M$29M+7%$43.7M+55%$28.9M+338%$55.7M+403%
R&D$87.5M+21%$87.5M+9%$79.8M−4%$62.1M−28%$67M−23%$72.2M−17%$76M−5%$77.9M+26%$75.2M+12%$71.2M−1%$62.5M−18%$58.9M−25%
SG&A$27M−3%$29.9M+13%$31.4M+12%$39.6M+81%$39.3M+46%$42.3M+42%$43.8M+40%$37.6M−5%$34.6M−12%$36.4M−14%$38.9M−11%$39.3M+5%
−$118.4M+18%−$121.3M+13%−$117.7M+6%−$101.9M−7%−$89.1M−25%−$86.6M−29%−$121.2M+3%−$113.8M+12%−$94.9M+7%−$73.5M−15%−$81M−33%−$51.9M−54%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income−$115M+15%−$118.1M+12%−$114.4M+7%−$98.6M−8%−$85.1M−26%−$77M−35%−$118M+3%−$109.7M+11%−$93.7M+10%−$71.7M−7%−$79.7M−32%−$48.7M−56%
−$1.2M−$1.8M−$1.4M−$1.5M+206%−$1.5M+22%$1.6M−$1.8M+31%$2M−$2.4M+58%$184K−88%−$665K−64%−$1.4M
Net income−$113.8M+14%−$116.4M+11%−$113M+5%−$97.1M−9%−$83.5M−27%−$78.6M−33%−$116.2M+3%−$111.7M+15%−$91.3M+9%−$71.9M−9%−$79M−32%−$47.3M−58%
−$0.46−27%−$0.45−30%−$0.42−16%−$0.34−28%−$0.28−39%−$0.26−42%−$0.36−14%−$0.33−3%n/an/a−$0.19−47%−$0.11−67%
245.8M+56%255.9M+55%266.2M+25%284.8M+27%303.3M+23%304.9M+19%322.9M+21%334.5M+17%n/an/a418.5M+30%450.2M+35%

Gross profit: 13 periods, Q2 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 9 periods, Q4 FY11 to Q4 FY24: quarter's net income to common over its shares, to the cent.

Diluted shares: 8 periods, Q4 FY11 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Iovance Biotherapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
IOVAIovance Biotherapeutics$3.6Bn/mn/an/m11.2×+35%−89.1%
ADMAAdma Biologics$2.5B15.8×21.3×n/m4.8×+8%33.0%
VCELVericel$2.1B88.1×157×n/m6.8×+23%7.9%
KRYSKrystal Biotech$8.8B37.1×42.5×n/m19.9×+23%54.8%
RGENRepligen$9.8B237×123×n/m12.4×+16%5.3%
TECHBIO-TECHNE$11.4B63.2×62.0×n/m9.4×−0%15.0%
HALOHalozyme Therapeutics$14.6B38.5×21.3×n/m8.8×+41%24.9%
MGTXMeiraGTx$895.1M13.1×15.4×n/m2.3×n/m19.9%
NBIXNeurocrine Biosciences$14.8B21.3×42.6×n/m4.4×+34%20.9%
EXELExelixis$17.4B22.1×22.7×n/m7.1×+9%35.3%
ALNYAlnylam Pharmaceuticals$21.2B26.7×68.2×18.9×4.4×+95%16.8%
Peer median$10.6B31.9×42.6×18.9×7.0×+23%20.4%

More on Iovance Biotherapeutics

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .